



Remibrutinib demonstrated superior efficacy vs placebo and favorable safety in patients with chronic inducible urticaria in the phase 3 REMIND study

G. Mosnaim, A.M. Giménez-Arnau, L.F. Ensina, S.M. Ferrucci, L. Finklea, A. Fukunaga, K. Hayama, M. Hide, J.S. Kern, P.H. Li, J. Reed, H. Rockmann, S. Saini, P. Staubach, J. Xu, B. Yang, A. Burciu, L. Chen, C. Field, S. Haemmerle, K. Lheritier, M. Porter, M. Metz

Please use this [LINK](#) to access the abstract after June 8, 2026, once it is available on the congress website